{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:33:52Z","timestamp":1794018832057,"version":"4.8.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["22-ALG-04 M3"],"award-info":[{"award-number":["22-ALG-04 M3"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"DOI":"10.1186\/s12890-025-03500-8","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T09:21:45Z","timestamp":1737710505000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Activity of Aztreonam-avibactam and other \u03b2-lactamase inhibitor combinations against Gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2020\u20132022)"],"prefix":"10.1186","volume":"25","author":[{"given":"Helio S.","family":"Sader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. J.","family":"Ryan\u00a0Arends","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy B.","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"issue":"3","key":"3500_CR1","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.ccc.2013.03.007","volume":"29","author":"GB Nair","year":"2013","unstructured":"Nair GB, Niederman MS. Nosocomial pneumonia: Lessons learned. Crit Care Clin. 2013;29(3):521\u201346.","journal-title":"Crit Care Clin"},{"issue":"5","key":"3500_CR2","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","volume":"63","author":"AC Kalil","year":"2016","unstructured":"Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O\u2019Grady NP, Bartlett JG, Carratala J, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61\u2013111.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"3500_CR3","doi-asserted-by":"publisher","first-page":"e169","DOI":"10.1093\/cid\/ciaa1478","volume":"72","author":"PD Tamma","year":"2021","unstructured":"Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America Guidance on the treatment of extended-spectrum beta-lactamase Producing enterobacterales (ESBL-E), Carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis. 2021;72(7):e169\u201383.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"3500_CR4","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1007\/s10096-021-04296-1","volume":"40","author":"K Tompkins","year":"2021","unstructured":"Tompkins K, van Duin D. Treatment for carbapenem-resistant Enterobacterales infections: recent advances and future directions. Eur J Clin Microbiol Infect Dis. 2021;40(10):2053\u201368.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"2","key":"3500_CR5","doi-asserted-by":"publisher","first-page":"ofad046","DOI":"10.1093\/ofid\/ofad046","volume":"10","author":"HS Sader","year":"2023","unstructured":"Sader HS, Mendes RE, Carvalhaes CG, Kimbrough JH, Castanheira M. Changing epidemiology of carbapenemases among carbapenem- rResistant Enterobacterales from United States hospitals and the activity of aztreonam-avibactam against contemporary Enterobacterales (2019\u20132021). Open Forum Infect Dis. 2023;10(2):ofad046.","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"3500_CR6","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/jac\/dkz497","volume":"75","author":"OA Cornely","year":"2020","unstructured":"Cornely OA, Cisneros JM, Torre-Cisneros J, Rodriguez-Hernandez MJ, Tallon-Aguilar L, Calbo E, Horcajada JP, Queckenberg C, Zettelmeyer U, Arenz D, et al. Pharmacokinetics and safety of aztreonam\/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study. J Antimicrob Chemother. 2020;75(3):618\u201327.","journal-title":"J Antimicrob Chemother"},{"key":"3500_CR7","unstructured":"CLSI. M07Ed11. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 2018."},{"key":"3500_CR8","unstructured":"CLSI. M100Ed34. Performance standards for antimicrobial susceptibility testing: 32nd informational supplement. 2024."},{"key":"3500_CR9","unstructured":"US FDA. Recognized Antimicrobial Susceptibility Test Interpretive Criteria. Available at: https:\/\/www.fda.gov\/drugs\/development-resources\/fda-recognized-antimicrobial-susceptibility-test-interpretive-criteria. Accessed 13 March 2024."},{"key":"3500_CR10","unstructured":"EUCAST: Breakpoint tables for interpretation of MICs and zone diameters. European Committee on Antimicrobial Susceptibility Testing; 2023."},{"issue":"5","key":"3500_CR11","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1089\/cmb.2012.0021","volume":"19","author":"A Bankevich","year":"2012","unstructured":"Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, Nikolenko SI, Pham S, Prjibelski AD, et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol. 2012;19(5):455\u201377.","journal-title":"J Comput Biol"},{"issue":"1","key":"3500_CR12","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1186\/s12879-022-07755-y","volume":"22","author":"MD Zilberberg","year":"2022","unstructured":"Zilberberg MD, Nathanson BH, Puzniak LA, Dillon RJ, Shorr AF. The risk of inappropriate empiric treatment and its outcomes based on pathogens in non-ventilated (nvHABP), ventilated (vHABP) hospital-acquired and ventilator-associated (VABP) bacterial pneumonia in the US, 2012\u20132019. BMC Infect Dis. 2022;22(1):775.","journal-title":"BMC Infect Dis"},{"issue":"Suppl 3","key":"3500_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.37201\/req\/s03.06.2022","volume":"35","author":"EP Plata-Menchaca","year":"2022","unstructured":"Plata-Menchaca EP, Ferrer R. Current treatment of nosocomial pneumonia and ventilator-associated pneumonia. Rev Esp Quimioter. 2022;35(Suppl 3):25\u20139.","journal-title":"Rev Esp Quimioter"},{"issue":"3","key":"3500_CR14","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1017\/ice.2021.464","volume":"43","author":"MD Zilberberg","year":"2022","unstructured":"Zilberberg MD, Nathanson BH, Puzniak LA, Shorr AF. Microbiology, empiric therapy and its impact on the outcomes of nonventilated hospital-acquired, ventilated hospital-acquired, and ventilator-associated bacterial pneumonia in the United States, 2014\u20132019. Infect Control Hosp Epidemiol. 2022;43(3):277\u201383.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"1","key":"3500_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/ice.2017.236","volume":"39","author":"JG Lake","year":"2018","unstructured":"Lake JG, Weiner LM, Milstone AM, Saiman L, Magill SS, See I. Pathogen distribution and antimicrobial resistance among pediatric healthcare-associated infections reported to the National Healthcare Safety Network, 2011\u20132014. Infect Control Hosp Epidemiol. 2018;39(1):1\u201311.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"6","key":"3500_CR16","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1093\/jac\/dkz074","volume":"74","author":"HS Sader","year":"2019","unstructured":"Sader HS, Castanheira M, Arends SJR, Goossens H, Flamm RK. Geographical and temporal variation in the frequency and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bacterial pneumonia: results from 20 years of the SENTRY Antimicrobial Surveillance Program (1997\u20132016). J Antimicrob Chemother. 2019;74(6):1595\u2013606.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"3500_CR17","doi-asserted-by":"publisher","first-page":"dlab117","DOI":"10.1093\/jacamr\/dlab117","volume":"3","author":"HS Sader","year":"2021","unstructured":"Sader HS, Streit JM, Carvalhaes CG, Huband MD, Shortridge D, Mendes RE, Castanheira M. Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from respiratory samples of patients hospitalized with pneumonia in Western Europe, Eastern Europe and the USA: Results from the SENTRY Antimicrobial Surveillance Program (2016-19). JAC Antimicrob Resist. 2021;3(3):dlab117.","journal-title":"JAC Antimicrob Resist"},{"issue":"1","key":"3500_CR18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13613-023-01144-7","volume":"13","author":"L Chen","year":"2023","unstructured":"Chen L, Hua J, Hong S, Yuan C, Jing R, Luo X, Zhu Y, Le L, Wang Z, Sun X, et al. Assessment of the relative benefits of monotherapy and combination therapy approaches to the treatment of hospital-acquired Stenotrophomonas maltophilia pneumonia: a multicenter, observational, real-world study. Ann Intensive Care. 2023;13(1):47.","journal-title":"Ann Intensive Care"},{"issue":"Suppl 1","key":"3500_CR19","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1093\/ofid\/ofy345","volume":"6","author":"HS Sader","year":"2019","unstructured":"Sader HS, Rhomberg PR, Fuhrmeister AS, Mendes RE, Flamm RK, Jones RN. Antimicrobial resistance surveillance and new drug development. Open Forum Infect Dis. 2019;6(Suppl 1):S5\u201313.","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"3500_CR20","doi-asserted-by":"publisher","first-page":"e0140622","DOI":"10.1128\/aac.01406-22","volume":"67","author":"M Estabrook","year":"2023","unstructured":"Estabrook M, Muyldermans A, Sahm D, Pierard D, Stone G, Utt E. Epidemiology of resistance determinants identified in meropenem-nonsusceptible Enterobacterales collected as part of a global surveillance study, 2018 to 2019. Antimicrob Agents Chemother. 2023;67(5):e0140622.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"3500_CR21","doi-asserted-by":"publisher","first-page":"e0018922","DOI":"10.1128\/aac.00189-22","volume":"66","author":"JA Karlowsky","year":"2022","unstructured":"Karlowsky JA, Lob SH, DeRyke CA, Hilbert DW, Wong MT, Young K, Siddiqui F, Motyl MR, Sahm DF. In vitro activity of ceftolozane-tazobactam, imipenem-relebactam, ceftazidime-avibactam, and comparators against Pseudomonas aeruginosa isolates collected in United States hospitals according to results from the SMART Surveillance Program, 2018 to 2020. Antimicrob Agents Chemother. 2022;66(5):e0018922.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"3500_CR22","doi-asserted-by":"publisher","first-page":"114833","DOI":"10.1016\/j.diagmicrobio.2019.05.005","volume":"96","author":"HS Sader","year":"2020","unstructured":"Sader HS, Flamm RK, Carvalhaes CG, Castanheira M. Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017\u20132018). Diagn Microbiol Infect Dis. 2020;96(3):114833.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"3500_CR23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.diagmicrobio.2018.04.012","volume":"92","author":"HS Sader","year":"2018","unstructured":"Sader HS, Castanheira M, Duncan LR, Flamm RK. Antimicrobial susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa isolates from United States Medical centers stratified by infection type: results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015\u20132016. Diagn Microbiol Infect Dis. 2018;92(1):69\u201374.","journal-title":"Diagn Microbiol Infect Dis"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-03500-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-025-03500-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-03500-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T09:21:48Z","timestamp":1737710508000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-025-03500-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3500"],"URL":"https:\/\/doi.org\/10.1186\/s12890-025-03500-8","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"4 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study does not include factors necessitating patient consent. The study used bacterial isolates stored by clinical laboratories and the participant laboratories did not provide patient identification.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}